Crystal morphology of menin inhibitors
Crystalline forms of a specific menin inhibitor disrupt the menin-MLL interaction, addressing the inadequacies of current leukemia treatments by targeting the underlying cause of oncogenic activity.
JP2026524748APending Publication Date: 2026-07-24KURA ONCOLOGY INC
1 Cites 0 Cited by
Patent Information
- Application Number
- JP2025558129
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-06-03
- Filing Date
- 2024-07-16
- Publication Date
- 2026-07-24
AI Technical Summary
Technical Problem
Current treatments for leukemia, particularly those involving MLL fusion proteins, are inadequate in targeting the interaction between menin and MLL fusion proteins, which contributes to oncogenic activity and leukemia development.
Method used
Development of crystalline forms of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine-4-yl)amino)piperidine-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazine-1-yl)propyl)-1H-indole-2-carbonitrile or its solvates, which act as menin inhibitors to disrupt this interaction.
Benefits of technology
The crystalline forms effectively inhibit the interaction between menin and MLL proteins, potentially providing therapeutic benefits for leukemia and other related diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
This specification describes the crystalline form of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine-4-yl)amino)piperidine-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazine-1-yl)propyl)-1H-indole-2-carbonitride or its solvate.
Need to check novelty before this filing date? Find Prior Art